SCHEMBL756665

SCHEMBL756665

Cc1cccc(OC[C]=O)c1

nearest known ligand 0.51

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
ACHE P22303 1/20 0.50
HTT P42858 1/20 0.48
KMT2A Q03164 2/20 0.47
GAA P10253 1/20 0.47
LMNA P02545 1/20 0.47
TDP1 Q9NUW8 2/20 0.46
ADRB2 P07550 1/20 0.46
ADRB1 P08588 1/20 0.46
RAB9A P51151 1/20 0.46
DRD2 P14416 2/20 0.46
DRD4 P21917 2/20 0.46
L3MBTL1 Q9Y468 1/20 0.45
DRD3 P35462 1/20 0.45
MAOB P27338 1/20 0.45
ALDH1A1 P00352 1/20 0.44
SMN1; SMN2 Q16637 1/20 0.44
POLB P06746 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5254418 0.81 LMNA (0.56) LMNAMAOB
SCHEMBL11686736 0.81 TP53 (0.53) HTTKMT2AGAALMNATDP1
SCHEMBL4815490 0.81 MAOB (0.52) ACHEKMT2AGAADRD2DRD4
SCHEMBL8195129 0.81 ACHE (0.50) ACHEHTTKMT2AGAALMNA
SCHEMBL12879342 0.79 ACHE (0.48) ACHEHTTKMT2AGAALMNA
SCHEMBL9571992 0.78 SOD1 (0.55) KMT2AGAALMNATDP1L3MBTL1
SCHEMBL7872947 0.78 ACHE (0.52) ACHEHTTKMT2AGAALMNA
SCHEMBL14085290 0.78 ACHE (0.47) ACHEKMT2AGAATDP1DRD2
SCHEMBL2098483 0.78 ACHE (0.56) ACHEHTTKMT2AGAALMNA
SCHEMBL10511421 0.77 ACHE (0.60) ACHEKMT2AGAALMNATDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080207706-A1 THIADIAZOLINE DERIVATIVE KYOWA HAKKO KOGYO CO., LTD (JP) 2008-08-28 US claimed
US-20060074113-A1 Thiadiazoline derivative KYOWA KIRIN CO., LTD. (JP) 2006-04-06 US claimed
EP-1454903-A1 THIADIAZOLINE DERIVATIVE KYOWA HAKKO KOGYO CO., LTD. (JP) 2004-09-08 EP claimed
EP-0469888-B1 Amidobenzenes ICI PLC (GB) 1994-09-28 EP claimed
US-5250570-A Aldose reductase inhibitors for controlling side effects of diabetes and galactosemia IMPERIAL CHEMICAL INDUSTRIES PLC (GB) 1993-10-05 US claimed
EP-0469888-A1 Amidobenzenes IMPERIAL CHEMICAL INDUSTRIES PLC (GB) 1992-02-05 EP claimed
WO-2024129931-A1 ALPHA-V BETA-6(ανβ6) INTEGRIN LIGANDS FOR EXTRAHEPATIC DELIVERY ALNYLAM PHARMACEUTICALS, INC. (US) 2024-06-20 WO disclosed
WO-2024010005-A1 METHOD FOR PREVENTING INSECT DAMAGE TO PLANTS 味の素株式会社 2024-01-11 WO disclosed
WO-2023195475-A1 METHOD FOR CONTROLLING PARASITIC PLANTS 味の素株式会社 2023-10-12 WO disclosed
US-20230210110-A1 METHOD FOR INDUCING ENVIRONMENTAL STRESS TOLERANCE IN PLANTS AJINOMOTO CO., INC. (JP) 2023-07-06 US disclosed
EP-4169381-A1 METHOD FOR INDUCING ENVIRONMENTAL STRESS TOLERANCE IN PLANTS AJINOMOTO CO., INC. (JP) 2023-04-26 EP disclosed
EP-1847534-B9 Thiadiazoline derivatives for treating cancer KYOWA HAKKO KIRIN CO LTD (JP) 2012-03-21 EP disclosed
EP-1847534-B1 Thiadiazoline derivatives for treating cancer KYOWA HAKKO KIRIN CO LTD (JP) 2011-06-22 EP disclosed
US-5250570-A Aldose reductase inhibitors for controlling side effects of diabetes and galactosemia IMPERIAL CHEMICAL INDUSTRIES PLC (GB) 1993-10-05 US disclosed
EP-0469888-A1 Amidobenzenes IMPERIAL CHEMICAL INDUSTRIES PLC (GB) 1992-02-05 EP disclosed
EP-0450097-A1 BENZOHETEROCYCLIC COMPOUNDS. OTSUKA PHARMA CO LTD (JP) 1991-10-09 EP disclosed
WO-1991005549-A1 BENZOHETEROCYCLIC COMPOUNDS OTSUKA PHARMACEUTICAL CO., LTD. (JP) 1991-05-02 WO disclosed
US-4044000-A Substituted β-lactam antibiotics ELI LILLY AND COMPANY (US) 1977-08-23 US disclosed
US-4042472-A Electrolytic process for 7-methoxy-3-exomethylenecepham compounds ELI LILLY AND COMPANY (US) 1977-08-16 US disclosed
US-3994885-A WITH ALKALI METAL ALKOXIDE, HALOGENATION ELI LILLY AND COMPANY (US) 1976-11-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060074113-A1 Thiadiazoline derivative BRWD1, RB1, ARG2 ACHE 4649/4885HTT 3957/4885KMT2A 558/4885
US-20230210110-A1 METHOD FOR INDUCING ENVIRONMENTAL STRESS TOLERANCE IN PLANTS DAO, ALAD, BCAT1 ACHE 2527/4885HTT 4586/4885KMT2A 3796/4885
US-20080207706-A1 THIADIAZOLINE DERIVATIVE BRWD1, RB1, ARG2 ACHE 4649/4885HTT 3957/4885KMT2A 558/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.